doi:10.3969/j.issn.1004-583X.2022.07.016

Abstract

CLC Number:

R730.26

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.07.016

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I7/663

References 46

[1]	Sung H, Ferlay J, Rebecca LS, et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660 URL
[2]	Ozkan EE, Kaymak Cerkesli ZA, Erdogan M. Predictive value of immune-inflammation indices in metabolic response and outcome after curative radiotherapy in patients with non-small cell lung cancer[J]. Clin Respir J, 2020, 14(9):849-856. doi: 10.1111/crj.13217 pmid: 32421891
[3]	郑开文. 炎症标志物在恶性肿瘤患者预后预测中应用效力的探索[D]. 长春: 吉林大学, 2020.
[4]	Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation[J]. Nature, 2008, 454(7203):436-444. doi: 10.1038/nature07205 URL
[5]	Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013 pmid: 21376230
[6]	Balkwill F, Mantovani A. Inflammation and cancer: Back to Virchow?[J]. Lancet, 2001, 357(9255):539-545. doi: 10.1016/S0140-6736(00)04046-0 pmid: 11229684
[7]	Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation[J]. Cell, 2011, 144(5):646-674. doi: 10.1016/j.cell.2011.02.013 pmid: 21376230
[8]	Matsubara T, Takamori S, Haratake N, et al. Identifification of the best prognostic marker among immunonutritional parameters using serum C-reactive protein and albumin in Non-small cell lung cancer[J]. Ann Surg Oncol, 2021, 28(6):3046-3054. doi: 10.1245/s10434-020-09230-x pmid: 33084992
[9]	马书梅. 2289例肺癌患者临床流行病学特征分析[D]. 济宁: 济宁医学院, 2020.
[10]	吴丽, 郑玲. 炎性复合指标与非小细胞肺癌预后关系的研究进展[J]. 现代肿瘤医学, 2019, 27(2):342-345.
[11]	Yee PP, Wei Y, Kim SY, et al. Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression[J]. Nat Commun, 2020, 11(1):5424. doi: 10.1038/s41467-020-19193-y pmid: 33110073
[12]	张洁, 张小陆, 于杰, 等. 治疗前中性粒细胞与淋巴细胞比值对小细胞肺癌患者预后的意义[J]. 河北医科大学学报, 2019, 40(3):292-295.
[13]	Weng J, Huang J, Yu W, et al. Combination of albumin concentration and neutrophil-to-lymphocyte ratio for predicting overall survival of patients with non-small cell lung cancer[J]. J Thorac Dis, 2021, 13(9):5508-5516. doi: 10.21037/jtd-21-1320 pmid: 34659817
[14]	Palomar-Abril V, Soria-Comes T, Campos ST, et al. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy[J]. Clin Transl Oncol, 2020, 22(12):2333-2340. doi: 10.1007/s12094-020-02396-6 URL
[15]	Fujimoto A, Toyokawa G, Koutake Y, et al. Association between pretreatment neutrophil-to-lymphocyte ratio and immune-related adverse events due to immune checkpoint inhibitors in patients with non-small cell lung cancer[J]. Thorac Cancer, 2021, 12(15):2198-2204. doi: 10.1111/1759-7714.14063 URL
[16]	Gavrilov S, Zhudenkov K, Helmlinger G, et al. Longitudinal tumor size and neutrophil-to-lymphocyte ratio are prognostic biomarkers for overall survival in patients with advanced Non-small cell lung cancer treated with durvalumab[J]. CPT Pharmacometrics Syst Pharmacol, 2021, 10(1):67-74. doi: 10.1002/psp4.12578 URL
[17]	陈晓博, 王倩, 李庆霞, 等. 系统性免疫炎症指数与非小细胞肺癌患者预后关系的研究进展[J]. 肿瘤防治研究杂志, 2021, 48(6):652-656.
[18]	Trac N, Chen LY, Zhang A, et al. CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation[J]. J Control Release, 2021, 329:614-623. doi: 10.1016/j.jconrel.2020.09.054 URL
[19]	Casanova-Acebes M, Dalla E, Leader AM. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells[J]. Nature, 2021, 595(7868):578-584. doi: 10.1038/s41586-021-03651-8 URL
[20]	Yuan C, Li N, Mao X, et al. Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort[J]. Thorac Cancer, 2017, 8(4):350-358. doi: 10.1111/1759-7714.12454 pmid: 28544400
[21]	张利平. 单核细胞与淋巴细胞比率、纤维蛋白原与白蛋白比率在肺癌诊断中的作用[D]. 南昌: 南昌大学, 2021.
[22]	Gao Y, Zhang H, Li Y, et al. Preoperative pulmonary function correlates with systemic inflammatory response and prognosis in patients with non-small cell lung cancer:results of a single institution retrospective study[J]. Oncotarget, 2017, 8(16):27489-27501. doi: 10.18632/oncotarget.14225 URL
[23]	Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells[J]. Nature, 2016, 529(7586):298-306. doi: 10.1038/nature17038 URL
[24]	徐小峰, 戴宏宇, 乔建兵,等. 外周血NLR和PLR评估晚期非小细胞肺癌一线含铂双药化疗疗效和预后的价值[J]. 现代肿瘤医学, 2020, 28(15):2627-2631.
[25]	Łochowski M, Chałubińska-Fendler J, Zawadzka I, et al. The prognostic significance of preoperative platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios in patients operated for non-small cell lung cancer[J]. Cancer Manag Res, 2021, 13:7795-7802. doi: 10.2147/CMAR.S317705 pmid: 34675674
[26]	Liu KJ, Jiang GM, Fang NX, et al. Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer[J]. J Int Med Res, 2020, 48(12):300060520980205.
[27]	谢剑华, 刘苗苗, 彭丽丽, 等. 系统免疫炎症营养指数与非手术治疗老年非小细胞肺癌患者预后的关系研究[J]. 中国全科医学, 2022, 25(17):2082-2089. doi: 10.12114/j.issn.1007-9572.2022.0102
[28]	Coutu BG, Johnson KC, Bhirud A, et al. Systemic immune-inflammatory index association with survival in patients undergoing trimodality therapy for lung cancer[J]. Oncology, 2022, 100(5):247-256. doi: 10.1159/000520989 URL
[29]	李影, 刘苗苗, 何严璐琦, 等. 治疗前系统免疫-炎症指数、纤维蛋白原对非小细胞肺癌预后的评估价值[J]. 河北医科大学学报, 2021, 42(5):514-519.
[30]	Zhang Y, Chen B. Prognostic value of the advanced lung cancer inflammation index in patients with lung cancer:A meta-analysis[J]. Dis Markers, 2019, 2019:2513026.
[31]	Mandaliya H, Jones M, Oldmeadow C, et al. Prognostic biomarkers in stage IV non-small cell lung cancer(NSCLC):Neutrophil to lymphocyte ratio(NLR), lymphocyte to monocyte ratio(LMR), platelet to lymphocyte ratio(PLR) and advanced lung cancer inflammation index(ALI)[J]. Transl Lung Cancer Res, 2019, 8(6):886-894. doi: 10.21037/tlcr.2019.11.16 URL
[32]	Kobayashi S, Karube Y, Inoue T, et al. Advanced lung cancer inflammation index predicts outcomes of patients with pathological stage IA lung adenocarcinoma following surgical resection[J]. Ann Thorac Cardiovasc Surg, 2019, 25(2):87-94. doi: 10.5761/atcs.oa.18-00158 URL
[33]	Yamamoto M, Saito H, Uejima C, et al. Prognostic value of the combination of pre-and postoperative C-reactive protein in colorectal cancer patients[J]. Surg Today, 2018, 48(11):986-993. doi: 10.1007/s00595-018-1689-9 pmid: 29946884
[34]	Rielland M, Cantor DJ, Graveline R, et al. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression[J]. J Clin Invest, 2014, 124(5):2125-2135. doi: 10.1172/JCI72619 pmid: 24691445
[35]	刘丽荣, 侯芳芳, 张海波,等. 血清C反应蛋白与晚期非小细胞肺癌患者化疗疗效的相关性[J]. 中国临床研究, 2020, 33(6):778-780.
[36]	廖浪霞, 严达尊, 吴柱标, 等. 肺癌临床分期与C反应蛋白联合四项肿瘤标志物的相关性研究[J]. 实用医技杂志, 2018, 25(4):380-382.
[37]	Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer[J]. J Thorac Oncol, 2012, 7(4):655-662. doi: 10.1097/JTO.0b013e318244ffe1 pmid: 22425914
[38]	Fan H, Shao ZY, Xiao YY, et al. Comparison of the Glasgow prognostic score(GPS) and the modified Glasgow prognostic score(mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2016, 142(6):1285-1297. doi: 10.1007/s00432-015-2113-0 URL
[39]	Takamori S, Takada K, Shimokawa M, et al. Clinical utility of pretreatment glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors[J]. Lung Cancer, 2021, 152:27-33. doi: 10.1016/j.lungcan.2020.11.026 pmid: 33341085
[40]	Kishi T, Matsuo Y, Ueki N, et al. Pretreatment modified glasgow prognostic score predicts clinical outcomes after stereotactic body radiation therapy for early-stage non-small cell lung cancer[J]. Int J Radiat Oncol Biol Phys, 2015, 92(3):619-626. doi: 10.1016/j.ijrobp.2015.02.018 URL
[41]	王彦, 吴砚铭, 王彦文, 等. C反应蛋白/白蛋白比值与肺癌患者预后关系的meta分析[J]. 华西医学杂志, 2019, 34(1):50-57.
[42]	Araki T, Tateishi K, Sonehara K, et al. Clinical utility of the C-reactive Protein:albumin ratio in non-small cell lung cancer patients treated with nivolumab[J]. Thorac Cancer, 2021, 12(5):603-612. doi: 10.1111/1759-7714.13788 pmid: 33434414
[43]	Ni XF, Wu J, Ji M, et al. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 14(6):402-409. doi: 10.1111/ajco.13055 URL
[44]	王晓兰, 韩伟, 王莹. 营养免疫与系统炎症参数在非小细胞肺癌患者中的预后意义[J]. 肿瘤代谢与营养电子杂志, 2021, 8(5):519-524.
[45]	Sun K, Chen S, Xu J, et al. The prognostic significance of the prognostic nutritional index in cancer: A systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2014, 140:1537-1549. doi: 10.1007/s00432-014-1714-3 pmid: 24878931
[46]	Bozkaya Y, Köstek O, Sakin A, et al. Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?[J]. Support Care Cancer, 2020, 28(5):2273-2282. doi: 10.1007/s00520-019-05055-x pmid: 31471631

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 46

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yi Peng, Li Cuiling, Huang Xinjiang, Zeng Chunhua. Clinical analysis of 5 cases with precocious puberty caused by hypothalamic hamartomas treated with gonadotropin releasing hormone analogues [J]. Clinical Focus, 2024, 39(1): 53-56.
[2]	Tao Jianan, Li Wenqian, Ma Xiuwen, An Qi, Wang Xuehong. Meta-analysis of expression and clinical significance of HER-2 in hepatocellular carcinoma [J]. Clinical Focus, 2023, 38(12): 1067-1072.
[3]	Zhang Na, Sun Yue, Dong Han, Zhao Peng, Yang Xin, Qi Yuan, Wang Lingling. Correlation between the expression level of SPARC and prognosis in patients with non-small cell lung cancer: A meta-analysis [J]. Clinical Focus, 2023, 38(11): 972-978.
[4]	Liu Fei, Lin Zhichun, Yue Jianlan, Yin Liang, Huang Shiming. Meta-analysis of different positron emission tomography/computed tomography imaging agents in the diagnosis of gliomas [J]. Clinical Focus, 2023, 38(4): 302-307.
[5]	He Chendong, Ge Fenglin, Yang Wei. TFEB translocation renal cell carcinoma: A case and literature review [J]. Clinical Focus, 2022, 37(12): 1122-1126.
[6]	Jia Chengbang, Shen Lijuan, Sun Zhigang. The relationship between CEA, CA125 and NSE and the pathological characteristics of patients with NSCLC and the value of combined detection [J]. Clinical Focus, 2022, 37(11): 992-995.
[7]	He Chao, Huang Shaobin. Predicting the risk by FIB-4 on hepatocellular carcinoma in patients with chronic liver disease: A meta-analysis [J]. Clinical Focus, 2022, 37(9): 779-784.
[8]	Peng Yu, Jiang Zhihong, Wang Zhihai. Clinical and genetic analysis of a neonate with congenital central nervous system multiple malformation: An identification on mutations in VANGL1 genes [J]. Clinical Focus, 2022, 37(7): 640-643.
[9]	. [J]. Clinical Focus, 2022, 37(6): 564-567.
[10]	Li Qing, Zhong Wen, Liu Siqiang, Chen Yusheng, Li Hongru. Meta-analysis of PD-1/PD-L1 inhibitors in the treatment of patients with non-small cell lung cancer having brain metastases [J]. Clinical Focus, 2022, 37(5): 400-405.
[11]	He Yiwen, Qiao Tiankui. Clinical value of CEA, CA125, and CYFRA21-1 levels in efficacy evaluation of EGFR-TKIs in the treatment of EGFR mutation-positive non-small cell lung adenocarcinoma [J]. Clinical Focus, 2021, 36(3): 220-224.
[12]	Ye Dan, Zhang Jiabo, Yao Lingli, Guo Yu. Relations between the expression of cyclinD1, p27 and the ultrasonographic features of central lymph node metastasis in the PTMC [J]. Clinical Focus, 2021, 36(3): 262-265.
[13]	Bao Xinran, Ha Minwen. Prognostic value of NLR, PLR and CEA in advanced non-small cell lung cancer [J]. Clinical Focus, 2021, 36(2): 139-143.
[14]	Zhang Zhaoming, Yu Xiangfeng, Song Jihui. Application value of diffusionweighted magnetic resonance imaging combined with spectral imaging in evaluating glioma grade [J]. Clinical Focus, 2020, 35(12): 1106-1110.
[15]	. [J]. Clinical Focus, 2020, 35(12): 1137-1141.